35年的产业学术合作，为科学和患者带来突破性进展，拉霍亚免疫学研究所与协和麒麟续签为期三年的协议-动脉网

35-YEAR INDUSTRY-ACADEMIC PARTNERSHIP YIELDING GROUNDBREAKING ADVANCES FOR SCIENCE AND PATIENTS RENEWS FOR ANOTHER THREE YEARS BETWEEN LA JOLLA INSTITUTE FOR IMMUNOLOGY AND KYOWA KIRIN

CISION 等信源发布 2025-04-04 07:14



可切换为仅中文







-Agreement extends one of the world's most enduring alliances for drug discovery-

-协议延长了世界上持续时间最长的药物发现联盟之一-

-Landmark discoveries from partnership have led to novel drug candidates, including an immunotherapy for moderate to severe atopic dermatitis currently in Phase III clinical trials-

-合作伙伴关系的里程碑式发现已经带来了新的候选药物，其中包括一种目前正在III期临床试验中的中重度特应性皮炎免疫疗法-

- New focus on cell and gene therapies to accelerate novel treatments for patients with unmet medical needs -

- 新的细胞和基因疗法重点，以加速为未满足医疗需求的患者提供新型治疗方案 -

LA JOLLA, Calif. and

拉霍亚，加利福尼亚州和

PRINCETON, N.J.

普林斯顿，新泽西州

，

April 3, 2025

2025年4月3日

/PRNewswire/ -- A 35-year academic-industry partnership that has produced groundbreaking discoveries in immunology and supported first-in-class therapies for rare disease patients has entered its 36

/PRNewswire/ -- 一个持续了35年的学术与产业合作，已在免疫学领域取得突破性发现，并为罕见病患者提供了首例疗法，现已进入第36年。

year with the signing of a three-year research funding agreement between

年，随着签署了一份为期三年的研究资助协议，

La Jolla Institute for Immunology

拉霍亚免疫学研究所

(LJI), an independent nonprofit research organization in

(LJI)，一个独立的非营利研究组织，在

California

加利福尼亚州

, and Kyowa Kirin, Inc., the wholly-owned North American subsidiary of

，以及协和麒麟株式会社的全资北美子公司

Kyowa Kirin Co., Ltd

协和麒麟株式会社

。

(Kyowa Kirin, TSE: 4151), a

（协和麒麟，东证：4151），一家

Japan

日本

-based global specialty pharmaceutical company.

基于全球的专业制药公司。

The three-year agreement marks the latest milestone in one of the world's most enduring and prolific industry-academic collaborations, conceived in 1988 by a Japanese immunologist and funded by then Kirin Brewery's emerging pharmaceutical business to advance scientific exploration and immunologic research..

这项为期三年的协议标志着这一世界上最持久、最多产的产业学术合作之一的最新里程碑。该合作于1988年由一位日本免疫学家发起，并由当时的麒麟啤酒旗下新兴制药业务提供资助，旨在推动科学探索和免疫学研究。

Today, LJI ranks among the world's top five immunology institutions, whose renowned faculty have transformed basic understanding of human immunity and paved the way for important clinical advances. Simultaneously, Kyowa Kirin has evolved into a leading global specialty pharmaceutical company that develops novel therapies for patients with rare and debilitating diseases.

如今，LJI位列全球前五大免疫学机构之一，其著名的教职员工已经改变了人类对免疫系统的基本理解，并为重要的临床进展铺平了道路。同时，协和麒麟已经发展成为一家领先的全球专业制药公司，为罕见病和衰弱性疾病患者开发新型疗法。

The company markets three therapies in .

公司上市了三种治疗药物。

North America

北美

and more than 50 products worldwide in hematology-oncology, rare bone disease, and other therapeutic areas.

在全球血液学-肿瘤学、罕见骨骼疾病及其他治疗领域拥有50多种产品。

Together, the two organizations have created a unique alliance that blends the academic prowess of LJI with the drug development and commercialization expertise of Kyowa Kirin. Working side by side under one roof, scientists from LJI and Kyowa Kirin's

两家机构共同创建了一个独特的联盟，将LJI的学术实力与协和麒麟的药物开发和商业化专业知识相结合。在同一个屋檐下并肩工作，来自LJI和协和麒麟的科学家们

La Jolla

拉霍亚

laboratories partner on joint research programs while also pursuing independent projects that accelerate the mutual interests of science and patient health. To date, the partnership has included sponsored or collaborative research projects, with, as well as top-tier journal publications authored by LJI faculty..

实验室伙伴合作开展联合研究项目，同时也追求加速科学和患者健康共同利益的独立项目。迄今为止，该合作伙伴关系已包括赞助或合作研究项目，以及由LJI教职人员撰写的顶级期刊出版物。

LJI scientists have made pioneering discoveries that harness the immune system against cancer, reveal key differences between the immune systems of men and women, and provide new opportunities to protect against emerging and infectious diseases.

LJI 科学家们取得了开创性的发现，利用免疫系统对抗癌症，揭示男性和女性免疫系统的关键差异，并提供保护免受新兴和传染病威胁的新机会。

'The unique and vibrant culture we've established over the past 35 years, coupled with the continuous research funding from Kyowa Kirin, has enabled our teams to make pioneering scientific contributions that have dramatically increased our understanding of human immunology,' said LJI Professor, President & CEO .

“我们过去35年建立的独特而充满活力的文化，加上来自协和麒麟的持续研究资金支持，使我们的团队能够做出开创性的科学贡献，极大地提高了我们对人类免疫学的理解，”LJI教授、总裁兼首席执行官表示。

Erica Ollmann Saphire

埃里卡·奥尔曼·萨菲尔

, Ph.D., MBA. 'Further, our proximity and open access to one another's respective scientific expertise, technical capabilities, and LJI's core facilities have fueled the identification and validation of target molecules as well as numerous candidate compounds adding life-changing value to the research we do.'.

，哲学博士，工商管理硕士。“此外，我们彼此接近且开放共享各自的科学专业知识、技术能力和LJI的核心设施，这促进了靶分子的识别和验证，以及众多候选化合物的发现，为我们的研究增添了改变生命的价值。”

Kyowa Kirin's research team has advanced several of these compounds into clinical trials for a range of conditions, including ulcerative colitis, acute respiratory distress, atopic dermatitis, with preliminary data anticipated in 2025.

京和麒麟（Kyowa Kirin）的研究团队已将其中几种化合物推进到针对多种疾病的临床试验阶段，包括溃疡性结肠炎、急性呼吸窘迫综合征和特应性皮炎，初步数据预计将在2025年公布。

'We're excited about our future with LJI and the opportunities it affords to shape a healthier future for patients with unmet medical needs,' said

“我们对与LJI的未来感到兴奋，它为满足未满足医疗需求的患者塑造更健康的未来提供了机会，”

Yoshifumi Torii

鸟居义文

, Ph.D., Executive Officer, Senior Vice President, Head of Global Research at Kyowa Kirin. 'Pairing the best basic scientists and translational medicine researchers at the table from the beginning creates a more entrepreneurial way of thinking about drug discovery and development that promotes innovation and accelerates timelines on behalf of patients.'.

博士，执行官，高级副总裁，协和麒麟全球研究主管。“从一开始就让最优秀的基础科学家和转化医学研究人员参与进来，可以创造一种更具创业精神的药物发现和开发思维方式，这种思维方式促进创新并加快为患者服务的时间表。”

The renewed research agreement provides LJI with multiple types of support, including research funding, faculty hiring support, and project-specific research funds relating to Kyowa Kirin's therapeutic scope. Joint research will prioritize cell and gene therapies designed to treat diseases with limited or no treatment options.

更新后的研究协议为LJI提供了多种支持，包括研究资金、教职人员聘用支持以及与协和麒麟治疗领域相关的特定项目研究基金。联合研究将优先考虑针对治疗选择有限或无治疗选项的疾病的细胞和基因疗法。

This focus aligns with Kyowa Kirin's commitment to addressing some of the world's most challenging and unmet medical needs..

这一重点与协和麒麟致力于解决一些世界上最具挑战性和未满足的医疗需求的承诺相一致。

About Kyowa Kirin

关于协和麒麟

Kyowa Kirin aims to discover novel medicines and treatments with life-changing value. As a

京和麒麟旨在发现具有改变生命价值的新药物和治疗方法。作为一家

Japan

日本

-based global specialty pharmaceutical company, we have invested in drug discovery and biotechnology innovation for more than 70 years. We are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, including rare bone & mineral disorders, intractable hematologic diseases, and other hematologic/oncologic diseases.

基于全球的专业制药公司，我们已在药物发现和生物技术创新领域投资了70多年。我们目前正致力于开发下一代抗体、细胞和基因疗法，这些疗法有潜力帮助那些具有高度未满足医疗需求的患者，包括罕见的骨骼与矿物质疾病、难治性血液病以及其他血液学/肿瘤学疾病。

A shared commitment to our values, to sustainable growth, and to making people smile unites us across the globe. You can learn more at .

我们对价值观、可持续增长以及让人们微笑的共同承诺将我们团结在一起。您可以在此处了解更多信息。

www.kyowakirin.com

。

About La Jolla Institute for Immunology

关于拉霍亚免疫学研究所

The La Jolla Institute for Immunology is dedicated to understanding the intricacies and power of the immune system so that we may apply that knowledge to promote human health and prevent a wide range of diseases. Since its founding in 1988 as an independent, nonprofit research organization, the Institute has made numerous advances leading toward its goal: .

拉霍亚免疫学研究所致力于理解免疫系统的复杂性和力量，以便我们能够运用这些知识促进人类健康并预防各种疾病。自1988年作为一个独立的非营利研究机构成立以来，该研究所已经取得了许多推动其目标实现的进展。

life without disease.

没有疾病的生活。

Visit

访问

lji.org

for more information.

更多信息，请参阅。

Media Contacts:

媒体联系人：

Gina Kirchweger

吉娜·基尔希韦格